Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961992 | 0.87 | CTSS (0.42) | NOTUMIDO1NISCHCTSSCTSK | |
| SCHEMBL16158539 | 0.86 | TP53 (0.41) | NOTUMIDO1NISCHFGFR1BCL2 | |
| SCHEMBL6952046 | 0.84 | HSD11B1 (0.39) | CTSSCTSKTP53 | |
| SCHEMBL2233428 | 0.83 | TSHR (0.34) | NOTUMIDO1MAP2K4 | |
| SCHEMBL3576499 | 0.83 | PRKCI (0.49) | FGFR1MGLLMAP2K4 | |
| SCHEMBL7810819 | 0.83 | CDK8 (0.41) | FGFR1 | |
| SCHEMBL1557945 | 0.83 | PIM1 (0.34) | NOTUMIDO1 | |
| SCHEMBL6740112 | 0.83 | NOTUM (0.34) | NOTUMIDO1 | |
| SCHEMBL17548483 | 0.83 | CYP4F2 (0.38) | NOTUMIDO1 | |
| SCHEMBL5950532 | 0.83 | PIM1 (0.31) | NOTUMIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| WO-2019154366-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏奥赛康药业有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-9783501-B2 | Substituted quinolines as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-04 | — | — | US | disclosed |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-04 | — | — | US | disclosed |
| US-9326513-B2 | Fungicidal compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2016-05-03 | — | — | US | disclosed |
| US-9326513-B2 | Fungicidal compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2016-05-03 | — | — | US | disclosed |
| WO-2016055028-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20150336945-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070066586-A1 | ANILINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2007-03-22 | — | — | US | disclosed |
| US-20060241132-A1 | Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1489081-A1 | SPIRO DERIVATIVES AND ADHESION MOLECULE INHIBITORS COMPRISING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2004-12-22 | — | — | EP | disclosed |
| CN-1159289-C | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases | ������˹ҩƷ��˾ | 2004-07-28 | — | — | CN | disclosed |
| EP-0711762-B1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-6277998-B1 | REACTING 2-CYANO-4-OXO-4H-BENZOPYRAN COMPOUND WITH HYDROGEN SULFIDE AND THEN REACTING PROUDCT WITH ALKYL HALIDE; REACTING THE PRODUCT WITH HYDRAZINE OR ITS SALT AND THEN WITH NITROUS ACID COMPOUND TO OBTAIN TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-21 | — | — | US | disclosed |
| US-6191289-B1 | REACTING A 4-OXO-4H-BENZOPYRAN GROUP SUBSTITUTED WITH AMIDE OR A PHENYL GROUP IN ITS 2 POSITION IS REACTED WITH ANHYDROUS HYDRAZINE OR SALT IN PRESENCE OF CATALYST FOLLOWED BY REACTING WITH NITROUS ACID OR SALT TO FORM TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-02-20 | — | — | US | disclosed |
| US-5874593-A | SULFUR CONTAINING AMIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0711762-A1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066586-A1 | ANILINE DERIVATIVES | SERPINB1, ACE, REN | NOTUM 74/4885IDO1 256/4885NISCH 89/4885 |
| US-20060241132-A1 | Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient | VCAM1, SELL, ICAM1 | NOTUM 2427/4885IDO1 2823/4885NISCH 4480/4885 |
| US-20150336945-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, SCN2A | NOTUM 3271/4885IDO1 2048/4885NISCH 465/4885 |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | NOTUM 1474/4885IDO1 2385/4885NISCH 766/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | NOTUM 1474/4885IDO1 2385/4885NISCH 766/4885 |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | CYP1B1, CYP4B1, DDT | NOTUM 353/4885IDO1 600/4885NISCH 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.